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Background
Combination therapy has been shown to improve cardio-
vascular outcomes in hypertensive, diabetic patients.
Amlodipine demonstrates beneficial pleiotropic effects
including improved endothelial function, enhanced angio-
genesis, and reduced cardiovascular risk. Telmisartan
exhibits similar beneficial cardiovascular effects in dia-
betic patients. Amlodipine in combination with telmisar-
tan may provide a synergistic benefit. In this study, dual
contrast CMR, using manganese (manganese-enhanced
MRI; MEMRI) and gadolinium (delayed-enhanced MRI;
DEMRI), will evaluate the viable myocardium and myo-
cardial scar, respectively, to investigate the underlying
mechanism of combined telmisartan and amlodipine
therapy.
Methods
Acute myocardial injury (AMI) was created by ligation
of the left anterior descending coronary artery (LAD) in
db/db mice. The mice were allocated to two groups: (1)
tap water (n = 17) and (2) addition of telmisartan
(10 mg/kg/day) and amlodipine (10 mg/kg/day) in the
tap water per os ad libitum following 1 week of conva-
lescence after AMI (n = 23). Dual contrast CMR with
manganese (MEMRI) and gadolinium (DEMRI) was per-
formed weekly with treatment to obtain LVEF and
assess viable myocardium and scar myocardium. After
the 4-week follow up period, contractile function was
assessed by pressure-volume (PV) loop analysis. Flow
cytometry of venous blood was performed to determine
the percentage of circulating endothelial progenitor cells.
Real-time PCR of the explanted myocardium was per-
formed to evaluate the expression of collagen I and III,
CTGF, TGFb, fibronectin and Akt.
Results
We demonstrate significantly improved left ventricular
function at weeks 1, 2, and 4 following combined telmi-
sartan and amlodipine therapy (32.0% ± 4.8%*, 31.8% ±
3.9%*, and 35.3% ± 2.3%*) compared to control (18.9% ±
1.5%, 21.8% ± 1.3%, and 15.7% ± 3.4%, *p < .05). PV loop
analysis also demonstrates improved systolic and diastolic
parameters with significantly increased maximum
pressure and dp/dt max and significantly decreased LV
end-diastolic pressure and Tau. MEMRI demonstrates
significantly increased viable myocardial volumes in the
treated mice (87.2% ± 0.92%*, 90.2% ± 1.3%*, and 91.4%
± 1.1%*) compared to control (80.5% ± 7.6%, 79.9% ±
3.1%, and 79.9% ± 3.1%, *p<0.05) throughout the study.
DEMRI scar volumes initially show no difference but
demonstrate a significantly decreased scar volume after 4
weeks of treatment. Furthermore, the measurement of
endothelial progenitor cells demonstrate a dramatic
increase in the treated compared to control mice (98.1%
± 0.25%* vs. 5.0% ± 2.6%, *p<0.05). However, no differen-
tial expression of fibrotic genes by PCR was observed.
Conclusions
This study provides potential evidence of salvage of the
injured myocardium by combined telmisartan and amlo-
dipine therapy, which could underlie the mechanism of
myocardial restoration after ischemic injury. Dual con-
trast CMR accurately identifies the dynamic effects on
both the viable myocardium and myocardial scar.
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